 |
|
|
| |
Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial
|
| |
| |
IDWeek 2021, September 29-October 3, 2021
Moti Ramgopal,1 Peter Ruane,2 Peter Shalit,3 Yongwu Shao,4 Ramin Ebrahimi,4 Alex Kintu,4 Christoph C. Carter,4 Moupali Das,4 Jared Baeten,4 Cynthia Brinson,5 Karam Mounzer6
1Midway Research Center, Fort Pierce, FL; 2Ruane Clinical Research Group, Inc., Los Angeles, CA; 3Peter Shalit MD & Associates, Seattle, WA; 4Gilead Sciences, Inc., Foster City, CA; 5Central Texas Clinical Research, Austin, TX; 6Philadelphia FIGHT Community Health Centers, Philadelphia, PA
References: 1. Mayer K, et al. Lancet. 2020;396:239-54; 2. Ogbuagu O, et al. Lancet HIV 2021;8:e397-e407.020; 3. Looker AC, et al. 2005-2008. National Center for Health Statistics. Vital Health Stat 11(251); 2012; 4. Hill JO, et al. Science 2003;299:853-5. Acknowledgments: We extend our thanks to the participants, their families, and all participating study investigators. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
